These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22918691)

  • 1. Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.
    Zinsmeister AR; Burton D; Camilleri M
    Dig Dis Sci; 2013 Feb; 58(2):509-18. PubMed ID: 22918691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
    Camilleri M; McKinzie S; Fox J; Foxx-Orenstein A; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions.
    Deiteren A; Camilleri M; Bharucha AE; Burton D; McKinzie S; Rao AS; Zinsmeister AR
    Neurogastroenterol Motil; 2010 Apr; 22(4):415-23, e95. PubMed ID: 20025675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.
    Rao AS; Wong BS; Camilleri M; Odunsi-Shiyanbade ST; McKinzie S; Ryks M; Burton D; Carlson P; Lamsam J; Singh R; Zinsmeister AR
    Gastroenterology; 2010 Nov; 139(5):1549-58, 1558.e1. PubMed ID: 20691689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.
    Odunsi-Shiyanbade ST; Camilleri M; McKinzie S; Burton D; Carlson P; Busciglio IA; Lamsam J; Singh R; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2010 Feb; 8(2):159-65. PubMed ID: 19879973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Colonic motility in humans. Recent physiological, pathophysiological and pharmacological data].
    Jouët P; Coffin B; Cuillerier E; Soulé JC; Flourié B; Lémann M
    Gastroenterol Clin Biol; 2000 Mar; 24(3):284-98. PubMed ID: 10804335
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM; Meyers NL; Hickling RI
    Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
    Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
    Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.
    Oduyebo I; Camilleri M; Nelson AD; Khemani D; Nord SL; Busciglio I; Burton D; Rhoten D; Ryks M; Carlson P; Donato L; Lueke A; Kim K; Rossi SJ; Zinsmeister AR
    Am J Gastroenterol; 2018 May; 113(5):725-734. PubMed ID: 29717197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.
    Lembo AJ; Cremonini F; Meyers N; Hickling R
    Aliment Pharmacol Ther; 2010 May; 31(9):979-90. PubMed ID: 20163375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study on the effect of linaclotide in patients with chronic constipation.
    Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
    Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort.
    Manabe N; Wong BS; Camilleri M; Burton D; McKinzie S; Zinsmeister AR
    Neurogastroenterol Motil; 2010 Mar; 22(3):293-e82. PubMed ID: 20025692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
    Acosta A; Camilleri M; Kolar G; Iturrino J; Szarka LA; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR; Spence SC; Gottesdiener K; Bouras EP; Vazquez-Roque MI
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2312-9.e1. PubMed ID: 26001337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.
    Farmer AD; Ruffle JK; Hobson AR
    Neurogastroenterol Motil; 2019 Feb; 31(2):e13492. PubMed ID: 30353623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation.
    Manini ML; Camilleri M; Goldberg M; Sweetser S; McKinzie S; Burton D; Wong S; Kitt MM; Li YP; Zinsmeister AR
    Neurogastroenterol Motil; 2010 Jan; 22(1):42-9, e7-8. PubMed ID: 19691492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study.
    Cremonini F; Camilleri M; McKinzie S; Carlson P; Camilleri CE; Burton D; Thomforde G; Urrutia R; Zinsmeister AR
    Am J Gastroenterol; 2005 Mar; 100(3):652-63. PubMed ID: 15743365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.